Skip to content

ANI Pharmaceuticals

US · ANIP #2919 by market cap Listed 1970
68.55 -0.58 -0.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.7 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
122.29% +4.68pp
Institutions
362 -4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund84.43%
Hedge Fund16.83%
Public Company9.06%
Individual/Insider6.21%
VC/PE Fund4.79%
Private Company3.91%
Government Pension Fund2.90%
Insurance Company0.25%

Top holders as of 2026-09-30

BlackRock 14.90% · 3.16M sh
MVP Capital Partners 4.79% · 1.01M sh
State Street Global Advisors 4.49% · 950.97K sh
American Century Investment Management 4.31% · 912.65K sh
Vanguard Capital Management, LLC 4.27% · 904.71K sh
Soleus Capital Management, L.P. 4.10% · 867.76K sh
Dimensional Fund Advisors 3.44% · 728.75K sh
Tang Capital Management, LLC 3.34% · 707.50K sh
UBS Asset Management 3.13% · 663.61K sh
Global Alpha Capital Management Ltd. 2.60% · 558.00K sh
Arrowstreet Capital, Limited Partnership 2.65% · 562.02K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 6 buys · 44 sells

NameRoleStake
Nikhil Lalwani Chief Executive Officer 1.58%
Chad Gassert Senior Vice President of Corporate Development & Strategy 1.10%
Stephen Carey Chief Financial Officer 0.78%
Muthusamy Shanmugam Head of R&D and COO of New Jersey Operations 0.39%
Ori Gutwerg Senior Vice President of Generics 0.36%
Meredith Cook Senior Vice President 0.35%
Christopher Mutz Senior Vp & Head of Rare Disease 0.29%
Krista Davis Chief Human Resources Officer 0.25%
Thomas Haughey Independent Chairperson 0.18%
Patrick Walsh Former Independent Chairperson 0.18%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-12 Meredith Cook Senior Vice President Automatic Disposition -500 $70.80
2026-10-28 Stephen Carey Chief Financial Officer Automatic Disposition -2,850 $72.87
2026-10-14 Nikhil Lalwani Chief Executive Officer Automatic Disposition -5,400 $71.89
2026-10-14 Nikhil Lalwani Chief Executive Officer Intent to Sell (Form 144) -5,400 $70.16
2026-10-12 Meredith Cook Senior Vice President Automatic Disposition -500 $73.59
2026-09-28 Stephen Carey Chief Financial Officer Automatic Disposition -2,850 $73.00
2026-09-14 Nikhil Lalwani Chief Executive Officer Automatic Disposition -5,400 $71.00
2026-09-13 Meredith Cook Senior Vice President Automatic Disposition -500 $70.79
2026-09-10 Jeanne Thoma Independent Director Automatic Disposition -1,000 $71.53
2026-08-30 Stephen Carey Chief Financial Officer Automatic Disposition -2,850 $72.80
2026-08-24 Nikhil Lalwani Chief Executive Officer Automatic Disposition -5,400 $74.30
2026-08-18 Henry Gosebruch Director Other Acquisition +6,662 --
2026-08-12 Meredith Cook Senior Vice President Automatic Disposition -500 $75.48
2026-08-09 Ori Gutwerg Senior Vice President of Generics Open Market Disposition -3,162 $77.00
2026-07-28 Stephen Carey Chief Financial Officer Automatic Disposition -2,850 $81.36
2026-07-17 Meredith Cook Senior Vice President Sale to Issuer -2,466 $79.20
2026-07-12 Meredith Cook Senior Vice President Automatic Disposition -500 $81.84
2026-07-06 Patrick Walsh Former Independent Chairperson Intent to Sell (Form 144) -4,336 $86.19
2026-07-01 Stephen Carey Chief Financial Officer Derivative Exercise and Sale -3,313 $49.51–86.00
2026-06-28 Stephen Carey Chief Financial Officer Automatic Disposition -2,850 $84.12

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.

ANI Pharmaceuticals discussion 0 comments

Add a comment